A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Condition: Castration-Resistant Prostatic Cancer Interventions: Drug: Niraparib; Drug: Abiraterone acetate (AA); Drug: Prednisone; Drug: Placebo for Niraparib Sponsor: Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Prednisone | Prostate Cancer | Research | Study